Literature DB >> 32682325

Amphetamine maintenance therapy during intermittent cocaine self-administration in rats attenuates psychomotor and dopamine sensitization and reduces addiction-like behavior.

Florence Allain1, Benoît Delignat-Lavaud2, Marie-Pierre Beaudoin2, Vincent Jacquemet1,3, Terry E Robinson4, Louis-Eric Trudeau1,2,5, Anne-Noël Samaha6,7.   

Abstract

D-amphetamine maintenance therapy shows promise as a treatment for people with cocaine addiction. Preclinical studies using Long Access (LgA) cocaine self-administration procedures suggest D-amphetamine may act by preventing tolerance to cocaine's effects at the dopamine transporter (DAT). However, Intermittent Access (IntA) cocaine self-administration better reflects human patterns of use, is especially effective in promoting addiction-relevant behaviors, and instead of tolerance, produces psychomotor, incentive, and neural sensitization. We asked, therefore, how D-amphetamine maintenance during IntA influences cocaine use and cocaine's potency at the DAT. Male rats self-administered cocaine intermittently (5 min ON, 25 min OFF x10; 5-h/session) for 14 sessions, with or without concomitant D-amphetamine maintenance therapy during these 14 sessions (5 mg/kg/day via s.c. osmotic minipump). We then assessed responding for cocaine under a progressive ratio schedule, responding under extinction and cocaine-primed reinstatement of drug seeking. We also assessed the ability of cocaine to inhibit dopamine uptake in the nucleus accumbens core using fast scan cyclic voltammetry ex vivo. IntA cocaine self-administration produced psychomotor (locomotor) sensitization, strong motivation to take and seek cocaine, and it increased cocaine's potency at the DAT. D-amphetamine co-administration suppressed the psychomotor sensitization produced by IntA cocaine experience. After cessation of D-amphetamine treatment, the motivation to take and seek cocaine was also reduced, and sensitization of cocaine's actions at the DAT was reversed. Thus, treatment with D-amphetamine might reduce cocaine use by preventing sensitization-related changes in cocaine potency at the DAT, consistent with an incentive-sensitization view of addiction.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32682325      PMCID: PMC7853073          DOI: 10.1038/s41386-020-0773-1

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  63 in total

1.  Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence.

Authors:  James Shearer; Alex Wodak; Ingrid van Beek; Richard P Mattick; John Lewis
Journal:  Addiction       Date:  2003-08       Impact factor: 6.526

Review 2.  Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: a comprehensive narrative overview of English-language studies.

Authors:  Benedikt Fischer; Peter Blanken; Dartiu Da Silveira; Andrea Gallassi; Elliot M Goldner; Jürgen Rehm; Mark Tyndall; Evan Wood
Journal:  Int J Drug Policy       Date:  2015-01-14

Review 3.  Agonist Medications for the Treatment of Cocaine Use Disorder.

Authors:  S Stevens Negus; Jack Henningfield
Journal:  Neuropsychopharmacology       Date:  2014-12-11       Impact factor: 7.853

4.  Cocaine addiction: treatments and future perspectives.

Authors:  Emilio Sánchez-Hervás
Journal:  Trends Psychiatry Psychother       Date:  2016 Oct-Dec

5.  Cocaine choice in humans during D-amphetamine maintenance.

Authors:  Craig R Rush; William W Stoops; Rajkamur J Sevak; Lon R Hays
Journal:  J Clin Psychopharmacol       Date:  2010-04       Impact factor: 3.153

6.  Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial.

Authors:  J Grabowski; H Rhoades; J Schmitz; A Stotts; L A Daruzska; D Creson; F G Moeller
Journal:  J Clin Psychopharmacol       Date:  2001-10       Impact factor: 3.153

7.  Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers.

Authors:  Mark K Greenwald; Leslie H Lundahl; Caren L Steinmiller
Journal:  Neuropsychopharmacology       Date:  2010-09-29       Impact factor: 7.853

8.  Prolonged attenuation of the reinforcing strength of cocaine by chronic d-amphetamine in rhesus monkeys.

Authors:  Paul W Czoty; Robert W Gould; Jennifer L Martelle; Michael A Nader
Journal:  Neuropsychopharmacology       Date:  2010-10-20       Impact factor: 7.853

9.  Pharmacological validation of a translational model of cocaine use disorder: Effects of d-amphetamine maintenance on choice between intravenous cocaine and a nondrug alternative in humans and rhesus monkeys.

Authors:  Joshua A Lile; Amy R Johnson; Matthew L Banks; Kevin W Hatton; Lon R Hays; Katherine L Nicholson; Justin L Poklis; Abner O Rayapati; Craig R Rush; William W Stoops; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2019-07-01       Impact factor: 3.157

10.  Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol.

Authors:  S Stevens Negus
Journal:  Neuropsychopharmacology       Date:  2003-03-05       Impact factor: 7.853

View more
  3 in total

1.  Intermittent access training produces greater motivation for a non-drug reinforcer than long access training.

Authors:  Madeline M Beasley; Tommy Gunawan; Brendan J Tunstall; David N Kearns
Journal:  Learn Behav       Date:  2022-02-07       Impact factor: 1.986

Review 2.  Dopamine 'ups and downs' in addiction revisited.

Authors:  Anne-Noël Samaha; Shaun Y-S Khoo; Carrie R Ferrario; Terry E Robinson
Journal:  Trends Neurosci       Date:  2021-04-20       Impact factor: 16.978

3.  Chloral Hydrate Alters Brain Activation Induced by Methamphetamine-Associated Cue and Prevents Relapse.

Authors:  Chenyu Jiang; Yunlong Xu; Jiafeng Zhong; Junyan Wu; Jian He; Wei Xu; Yingjie Zhu
Journal:  Front Mol Neurosci       Date:  2022-07-11       Impact factor: 6.261

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.